HK Stock Market Move | WuXi AppTec (02359) falls by nearly 4% at the close, previously announced the divestiture of overseas cell gene therapy business.

WuXi AppTec (02359) fell by nearly 4% in the closing session, and as of the time of publication, it was down 3.69% to HK$52.15 with a turnover of HK$1.57 billion. On the news front, on December 24, 2024, WuXi AppTec announced the sale of two operating entities in the US and UK engaged in high-end therapeutic CTDMO business, as well as the disposal of overseas cell and gene therapy business. WuXi AppTec stated that the transaction will not have a significant impact on the company's performance and operating conditions, and is expected to be completed in the first half of 2025. It is worth noting that according to the Hong Kong Stock Exchange filing, on January 7, Citigroup's long position in WuXi AppTec's H shares decreased from 5.05% to 4.11%, BlackRock's long position decreased from 5.26% to 4.70%, and JPMorgan's short position increased from 3.64% to 4.99%. On January 8, JPMorgan's long position in WuXi AppTec's H shares also decreased from 10.57% to 9.46%.